Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

In this episode of GEN's Touching Base, editors talk about Parabilis Medicines’ groundbreaking IPO score, a new Merck collaboration, first-in-human Lassa–Rabies vaccine data, how CRISPR is attacking cancer cells, and mRNA delivery for DMD therapy.

The post Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine appeared first on GEN - Genetic Engineering and Biotechnology News.